Sutro Biopharma, Inc. Forecast, price target & analysts
Sutro Biopharma, Inc. Target price 2025 - Analyst rating & recommendation
Sutro Biopharma, Inc. Classifications & Recommendation:
Sutro Biopharma, Inc. Price Target
| Target Price | $11.50 |
| Price | $1.55 |
| Potential |
641.94%
register free of charge
|
| Number of Estimates | 10 |
|
10 Analysts have issued a price target Sutro Biopharma, Inc. 2026 .
The average Sutro Biopharma, Inc. target price is $11.50.
This is
641.94%
register free of charge
$20.00
1,190.32%
register free of charge
$4.00
158.06%
register free of charge
|
|
| A rating was issued by 11 analysts: 10 Analysts recommend Sutro Biopharma, Inc. to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Sutro Biopharma, Inc. stock has an average upside potential 2026 of
641.94%
register free of charge
|
Sales and Margin forecast 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Revenue Million $ | 153.73 | 59.04 |
| 126.84% | 61.59% | |
| EBITDA Margin | -53.64% | -385.94% |
| 69.87% | 619.51% | |
| Net Margin | -95.41% | -404.46% |
| 66.61% | 323.92% |
11 Analysts have issued a sales forecast Sutro Biopharma, Inc. 2024 . The average Sutro Biopharma, Inc. sales estimate is
This results in the following potential growth metrics:
2 Analysts have issued an Sutro Biopharma, Inc. EBITDA forecast 2024. The average Sutro Biopharma, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
11 Sutro Biopharma, Inc. Analysts have issued a net profit forecast 2024. The average Sutro Biopharma, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.78 | -2.90 |
| 24.26% | 62.92% | |
| P/E | negative | |
| EV/Sales | negative |
11 Analysts have issued a Sutro Biopharma, Inc. forecast for earnings per share. The average Sutro Biopharma, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Sutro Biopharma, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Sutro Biopharma, Inc....
Current Sutro Biopharma, Inc. Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| JMP Securities | Locked ➜ Locked | Locked | Dec 11 2024 |
| Wells Fargo | Locked ➜ Locked | Locked | Dec 11 2024 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Nov 18 2024 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Oct 11 2024 |
| Piper Sandler | Locked ➜ Locked | Locked | Oct 11 2024 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Sep 16 2024 |
| JMP Securities | Locked ➜ Locked | Locked | Sep 16 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
JMP Securities: Locked ➜ Locked
|
Dec 11 2024 |
|
Locked
Wells Fargo: Locked ➜ Locked
|
Dec 11 2024 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Nov 18 2024 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Oct 11 2024 |
|
Locked
Piper Sandler: Locked ➜ Locked
|
Oct 11 2024 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Sep 16 2024 |
|
Locked
JMP Securities: Locked ➜ Locked
|
Sep 16 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
